Phase I trial of oral green tea extract in adult patients with solid tumors
- PMID: 11251015
- DOI: 10.1200/JCO.2001.19.6.1830
Phase I trial of oral green tea extract in adult patients with solid tumors
Abstract
Purpose: This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract (GTE) once daily or three times daily.
Patients and methods: Cohorts of three or more adult cancer patients were administered oral GTE with water after meals one or three times daily for 4 weeks, to a maximum of 6 months, depending on disease response and patient tolerance. Pharmacokinetic analyses were encouraged but optional.
Results: Dose levels of 0.5 to 5.05 g/m(2) qd and 1.0 to 2.2 g/m(2) tid were explored. A total of 49 patients were studied.
Patient characteristics: median age, 57 years (range, 27 to 77 years); 23 patients were women (47%); 98% had a Zubrod PS of 1%; 98% had PS of 1; and 21 had non-small-cell lung, 19 had head & neck cancer, three had mesothelioma, and six had other. Mild to moderate toxicities were seen at most dose levels and promptly reversed on discontinuation of GTE. Dose-limiting toxicities were caffeine related and included neurologic and gastrointestinal effects. The maximum-tolerated dose was 4.2 g/m(2) once daily or 1.0 g/m(2) three times daily. No major responses occurred; 10 patients with stable disease completed 6 months of GTE. Pharmacokinetic analyses found accumulation of caffeine levels that were dose dependent, whereas epigallocatechin gallate levels did not accumulate nor appear dose related.
Conclusion: A dose of 1.0 g/m(2) tid (equivalent to 7 to 8 Japanese cups [120 mL] of green tea three times daily) is recommended for future studies. The side effects of this preparation of GTE were caffeine related. Oral GTE at the doses studied can be taken safely for at least 6 months.
Similar articles
-
Chemoprevention of oral cancer: Green tea experience.J Nat Sci Biol Med. 2014 Jan;5(1):3-7. doi: 10.4103/0976-9668.127272. J Nat Sci Biol Med. 2014. PMID: 24678188 Free PMC article. Review.
-
Green tea and lung cancer: a systematic review.Integr Cancer Ther. 2013 Jan;12(1):7-24. doi: 10.1177/1534735412442378. Epub 2012 Apr 24. Integr Cancer Ther. 2013. PMID: 22532034 Review.
-
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.Cancer Prev Res (Phila). 2009 Nov;2(11):931-41. doi: 10.1158/1940-6207.CAPR-09-0121. Cancer Prev Res (Phila). 2009. PMID: 19892663 Free PMC article. Clinical Trial.
-
Phase I study of green tea extract in patients with advanced lung cancer.Cancer Chemother Pharmacol. 2005 Jan;55(1):33-8. doi: 10.1007/s00280-004-0859-1. Epub 2004 Aug 7. Cancer Chemother Pharmacol. 2005. PMID: 15309507 Clinical Trial.
-
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.J Clin Oncol. 2002 Sep 15;20(18):3815-25. doi: 10.1200/JCO.2002.03.038. J Clin Oncol. 2002. PMID: 12228201 Clinical Trial.
Cited by
-
Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome.Cancers (Basel). 2022 Aug 18;14(16):3988. doi: 10.3390/cancers14163988. Cancers (Basel). 2022. PMID: 36010981 Free PMC article. Review.
-
Prevention of carcinogen-induced oral cancers by polymeric black tea polyphenols via modulation of EGFR-Akt-mTOR pathway.Sci Rep. 2022 Aug 25;12(1):14516. doi: 10.1038/s41598-022-18680-0. Sci Rep. 2022. PMID: 36008552 Free PMC article.
-
Role of Phytochemicals in Cancer Chemoprevention: Insights.Antioxidants (Basel). 2021 Sep 14;10(9):1455. doi: 10.3390/antiox10091455. Antioxidants (Basel). 2021. PMID: 34573087 Free PMC article. Review.
-
Clinical Presentations and Outcomes of Coronavirus Disease 2019 in Patients With Solid Tumors.Cureus. 2021 Jun 5;13(6):e15452. doi: 10.7759/cureus.15452. eCollection 2021 Jun. Cureus. 2021. PMID: 34262803 Free PMC article.
-
Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth in vivo in head and neck cancer models.Oncol Rep. 2021 May;45(5):87. doi: 10.3892/or.2021.8038. Epub 2021 Apr 13. Oncol Rep. 2021. PMID: 33864659 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical